{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T21:32:25Z","timestamp":1772227945996,"version":"3.50.1"},"reference-count":50,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2019,8,1]]},"DOI":"10.1001\/jamaneurol.2019.1206","type":"journal-article","created":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T15:31:48Z","timestamp":1558366308000},"page":"978","source":"Crossref","is-referenced-by-count":20,"title":["Maximizing the Benefit of Life-Saving Treatments for Pompe Disease, Spinal Muscular Atrophy, and Duchenne Muscular Dystrophy Through Newborn Screening"],"prefix":"10.1001","volume":"76","author":[{"given":"Mei","family":"Baker","sequence":"first","affiliation":[{"name":"University of Wisconsin School of Medicine, Madison"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Griggs","sequence":"additional","affiliation":[{"name":"University of Rochester School of Medicine, Rochester, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Byrne","sequence":"additional","affiliation":[{"name":"University of Florida, Gainesville"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne M.","family":"Connolly","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Finkel","sequence":"additional","affiliation":[{"name":"Nemours Children\u2019s Hospital, Orlando, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucja","family":"Grajkowska","sequence":"additional","affiliation":[{"name":"Muscular Dystrophy Association, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Haidet-Phillips","sequence":"additional","affiliation":[{"name":"Muscular Dystrophy Association, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Hagerty","sequence":"additional","affiliation":[{"name":"Muscular Dystrophy Association, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Ostrander","sequence":"additional","affiliation":[{"name":"State University of New York Upstate Medical University, Rushville"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianna","family":"Orlando","sequence":"additional","affiliation":[{"name":"Muscular Dystrophy Association, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Swoboda","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Watson","sequence":"additional","affiliation":[{"name":"American College of Medical Genetics and Genomics, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Rodney","family":"Howell","sequence":"additional","affiliation":[{"name":"University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"2","key":"nsc190001r1","doi-asserted-by":"publisher","first-page":"e20162252","DOI":"10.1542\/peds.2016-2252","article-title":"Newborn sequencing in genomic medicine and public health.","volume":"139","author":"Berg","year":"2017","journal-title":"Pediatrics"},{"issue":"2","key":"nsc190001r2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/ana.24316","article-title":"Cystic fibrosis newborn screening: a model for neuromuscular disease screening?","volume":"77","author":"Scully","year":"2015","journal-title":"Ann Neurol"},{"issue":"4","key":"nsc190001r3","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s10545-007-0687-7","article-title":"Newborn screening in the Asia Pacific region.","volume":"30","author":"Padilla","year":"2007","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"nsc190001r4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1053\/j.semperi.2015.03.002","article-title":"Current status of newborn screening worldwide: 2015.","volume":"39","author":"Therrell","year":"2015","journal-title":"Semin Perinatol"},{"key":"nsc190001r5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.pediatrneurol.2017.08.012","article-title":"A historical and current review of newborn screening for neuromuscular disorders from around the world: lessons for the United States.","volume":"77","author":"Ross","year":"2017","journal-title":"Pediatr Neurol"},{"issue":"15","key":"nsc190001r6","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1001\/jama.2014.17488","article-title":"Newborn screening: evolving challenges in an era of rapid discovery.","volume":"313","author":"Bailey","year":"2015","journal-title":"JAMA"},{"issue":"11","key":"nsc190001r8","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/nm1112-1596","article-title":"Europe plays catch-up on neonatal screening as US skips ahead.","volume":"18","author":"Holmes","year":"2012","journal-title":"Nat Med"},{"issue":"8","key":"nsc190001r12","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/gim.2012.24","article-title":"Decision analysis, economic evaluation, and newborn screening: challenges and opportunities.","volume":"14","author":"Prosser","year":"2013","journal-title":"Genet Med"},{"issue":"2","key":"nsc190001r13","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1542\/peds.2013-2271","article-title":"Parental permission for pilot newborn screening research: guidelines from the NBSTRN.","volume":"133","author":"Botkin","year":"2014","journal-title":"Pediatrics"},{"issue":"11","key":"nsc190001r16","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1373\/clinchem.2016.258459","article-title":"Newborn screening for lysosomal storage disorders: quo vadis?","volume":"62","author":"Peake","year":"2016","journal-title":"Clin Chem"},{"issue":"2 Pt 2","key":"nsc190001r17","first-page":"389","article-title":"Serving the family from birth to the medical home: newborn screening: a blueprint for the future, a call for a national agenda on state newborn screening programs.","volume":"106","author":"AAP","year":"2000","journal-title":"Pediatrics"},{"issue":"7","key":"nsc190001r18","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/ajmg.a.v152a:7","article-title":"Newborn and carrier screening for spinal muscular atrophy.","volume":"152A","author":"Prior","year":"2010","journal-title":"Am J Med Genet A"},{"issue":"3","key":"nsc190001r19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy.","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann Neurol"},{"issue":"6","key":"nsc190001r22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1212\/WNL.0b013e318282334e","article-title":"Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data?","volume":"80","author":"Scully","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"nsc190001r23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/mus.v54.2","article-title":"Clinical follow-up for Duchenne muscular dystrophy newborn screening: a proposal.","volume":"54","author":"Kwon","year":"2016","journal-title":"Muscle Nerve"},{"key":"nsc190001r24","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1542\/peds.2016-0280C","article-title":"Newborn screening for pompe disease.","volume":"140","author":"Bodamer","year":"2017","journal-title":"Pediatrics"},{"issue":"18","key":"nsc190001r26","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy.","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"nsc190001r27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy.","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"nsc190001r28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jpeds.2017.06.042","article-title":"Presymptomatic diagnosis of spinal muscular atrophy through newborn screening.","volume":"190","author":"Chien","year":"2017","journal-title":"J Pediatr"},{"issue":"4","key":"nsc190001r30","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/mus.v53.4","article-title":"Twenty-year follow-up of newborn screening for patients with muscular dystrophy.","volume":"53","author":"Chung","year":"2016","journal-title":"Muscle Nerve"},{"issue":"3","key":"nsc190001r31","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jpeds.2009.02.007","article-title":"Delayed diagnosis in Duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet).","volume":"155","author":"Ciafaloni","year":"2009","journal-title":"J Pediatr"},{"issue":"1-2","key":"nsc190001r32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ymgme.2014.06.001","article-title":"A new day for Duchenne\u2019s?: the time has come for newborn screening.","volume":"113","author":"Pillers","year":"2014","journal-title":"Mol Genet Metab"},{"key":"nsc190001r33","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1542\/peds.2016-0280F","article-title":"The role of genetic counseling in Pompe disease after patients are identified through newborn screening.","volume":"140","author":"Atherton","year":"2017","journal-title":"Pediatrics"},{"key":"nsc190001r34","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1542\/peds.2016-0280D","article-title":"The initial evaluation of patients after positive newborn screening: recommended algorithms leading to a confirmed diagnosis of pompe disease.","volume":"140","author":"Burton","year":"2017","journal-title":"Pediatrics"},{"key":"nsc190001r35","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1542\/peds.2016-0280E","article-title":"Management of confirmed newborn-screened patients with Pompe disease across the disease spectrum.","volume":"140","author":"Kronn","year":"2017","journal-title":"Pediatrics"},{"issue":"7","key":"nsc190001r36","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/GIM.0b013e318220d523","article-title":"Technical standards and guidelines for spinal muscular atrophy testing.","volume":"13","author":"Prior","year":"2011","journal-title":"Genet Med"},{"issue":"2","key":"nsc190001r37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/JND-180304","article-title":"Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening.","volume":"5","author":"Glascock","year":"2018","journal-title":"J Neuromuscul Dis"},{"issue":"3","key":"nsc190001r38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/humu.v30:3","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum Mutat"},{"issue":"9","key":"nsc190001r39","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1177\/0883073810371129","article-title":"Read-through strategies for suppression of nonsense mutations in Duchenne\/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124).","volume":"25","author":"Finkel","year":"2010","journal-title":"J Child Neurol"},{"issue":"8","key":"nsc190001r40","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/gim.2017.194","article-title":"Precision newborn screening for lysosomal disorders.","volume":"20","author":"Minter Baerg","year":"2018","journal-title":"Genet Med"},{"issue":"2","key":"nsc190001r42","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1373\/clinchem.2014.231019","article-title":"Newborn blood spot screening test using multiplexed real-time PCR to simultaneously screen for spinal muscular atrophy and severe combined immunodeficiency.","volume":"61","author":"Taylor","year":"2015","journal-title":"Clin Chem"},{"issue":"3","key":"nsc190001r43","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ana.v81.3","article-title":"Emerging therapies and challenges in spinal muscular atrophy.","volume":"81","author":"Farrar","year":"2017","journal-title":"Ann Neurol"},{"issue":"6","key":"nsc190001r46","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1002\/ajmg.a.38220","article-title":"Newborn screening for spinal muscular atrophy: the views of affected families and adults.","volume":"173","author":"Boardman","year":"2017","journal-title":"Am J Med Genet A"},{"issue":"6","key":"nsc190001r48","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/gim.2017.152","article-title":"Pilot study of population-based newborn screening for spinal muscular atrophy in New York state.","volume":"20","author":"Kraszewski","year":"2018","journal-title":"Genet Med"},{"issue":"6","key":"nsc190001r49","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/mus.24100","article-title":"Parental attitudes toward newborn screening for Duchenne\/Becker muscular dystrophy and spinal muscular atrophy.","volume":"49","author":"Wood","year":"2014","journal-title":"Muscle Nerve"},{"issue":"1","key":"nsc190001r50","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1001\/jamaneurol.2015.3537","article-title":"Identifying non-Duchenne muscular dystrophy-positive and false negative results in prior Duchenne muscular dystrophy newborn screening programs: a review.","volume":"73","author":"Gatheridge","year":"2016","journal-title":"JAMA Neurol"},{"key":"nsc190001r44","author":"Bertini"},{"key":"nsc190001r7","unstructured":"CommissionE. Public health rare diseases screening. https:\/\/ec.europa.eu\/health\/rare_diseases\/screening_en. Accessed April 10, 2018."},{"key":"nsc190001r9","unstructured":"ACHDNC. Advisory committee on heritable disorders in newborns and children. https:\/\/www.hrsa.gov\/advisory-committees\/heritable-disorders\/about\/index.html. Accessed June 11, 2018."},{"key":"nsc190001r10","unstructured":"RUSP. Recommended Uniform Screening Panel. https:\/\/www.hrsa.gov\/advisory-committees\/heritable-disorders\/rusp\/index.html. Accessed February 18, 2018."},{"key":"nsc190001r11","unstructured":"KemperA. HRSA evidence report: newborn screening for pompe disease. https:\/\/www.hrsa.gov\/sites\/default\/files\/hrsa\/advisory-committees\/heritable-disorders\/rusp\/previous-nominations\/pompe-external-evidence-review-report-2013.pdf. Published 2013. Accessed June 11, 2018."},{"key":"nsc190001r14","unstructured":"Senate bill 1095. https:\/\/leginfo.legislature.ca.gov\/faces\/billNavClient.xhtml?bill_id=201520160SB1095. Accessed February 20, 2018."},{"key":"nsc190001r15","unstructured":"CS\/CS\/SB 1124: Newborn screenings. https:\/\/www.flsenate.gov\/Session\/Bill\/2017\/01124. Accessed February 20, 2018."},{"key":"nsc190001r20","unstructured":"APHL. APHL position statement: newborn screening follow-up. https:\/\/www.aphl.org\/policy\/Position_Documents\/NBS_2011_Newborn_Screening_Follow-up_Extension.pdf. Published 2011. Accessed June 21, 2018."},{"key":"nsc190001r21","unstructured":"ACMG. ACT sheets and algorithms. https:\/\/www.acmg.net\/ACMG\/Publications\/ACT_Sheets_and_Confirmatory_Algorithms\/ACMG\/Publications\/ACT_Sheets_and_Confirmatory_Algorithms\/ACT_sheets_Homepage.aspx?hkey=6d43e3d3-71fd-49f4-88d5-7197238f9f33. Accessed June 11, 2018."},{"key":"nsc190001r25","unstructured":"SMA C. HHS Secretary, Alex Azar, recommends nationwide newborn screening for SMA. http:\/\/www.curesma.org\/news\/nbs-update-july2018.html. Published 2018. Accessed July 28, 2018."},{"key":"nsc190001r29","unstructured":"US Food and Drug Administration. FDA approves first drug for spinal muscular atrophy. https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm534611.htm. Published 2016. Accessed July 28, 2018."},{"key":"nsc190001r41","unstructured":"Collaborative Laboratory Integrated Reports. https:\/\/clir.mayo.edu\/. Accessed April 10, 2018."},{"key":"nsc190001r45","unstructured":"NCT02386553. A study of multiple doses of nusinersen (ISIS 396443) delivered to infants with genetically diagnosed and presymptomatic spinal muscular atrophy (NURTURE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02386553. Accessed July 22, 2018."},{"key":"nsc190001r47","unstructured":"HRSA. Secretary\u2019s final response regarding the Committee\u2019s recommendation to add SMA https:\/\/www.hrsa.gov\/advisory-committees\/heritable-disorders\/recommendations-reports\/index.html. Accessed July 23, 2018."}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/article-pdf\/76\/8\/978\/17754354\/jamaneurology_baker_2019_sc_190001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T15:01:23Z","timestamp":1565622083000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2733675"}},"subtitle":["Essential Steps"],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2019.1206","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8,1]]}}}